6.58
-0.59(-8.23%)
Currency In USD
| Previous Close | 7.17 |
| Open | 6.86 |
| Day High | 6.86 |
| Day Low | 6.37 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 5.55 |
| Volume | 29,729 |
| Average Volume | 143,827 |
| Market Cap | 3.83M |
| PE | 0 |
| EPS | -2,258.79 |
| Moving Average 50 Days | 7.44 |
| Moving Average 200 Days | 16.06 |
| Change | -0.59 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of December 04, 2025 at a share price of $6.58. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.17 as of December 04, 2025 at a share price of $6.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managemen
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
GlobeNewswire Inc.
Nov 05, 2025 11:00 AM GMT
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
GlobeNewswire Inc.
Oct 22, 2025 10:00 AM GMT
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE